Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir

We are excited to share our modeling analysis on the Cost of Goods for the manufacturing of Molnupiravir, a critical, life-saving COVID-19 therapeutic. The paper is a result of collaboration between multiple organizations and LBG team members, and the conclusions identify multiple, alternative manufacturing methodologies, which can result in cost reductions through synthesis optimization.” – Chris Peterson, Sia/LBG

View Publication

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.